As of Friday close, VBI Vaccines Inc.’s (NASDAQ:VBIV) stock was up $0.14, moving up 14.63 percent to $1.06. The average number of shares traded per day over the past five days has been 1,245,120 shares. 4 times new highs have been achieved over the past 5 days, with a $0.2093 gain in that time frame. In the last twenty days, the average volume was 1,578,965, while in the previous 50 days, it was 2,463,458.
Since last month, VBIV stock rose 23.10%. Shares of the company fell to $0.7727 on 07/12/22, the lowest level in the past month. A 52-week high of $3.81 was reached on 01/03/22 after having rallying from a 52-week low of $0.64. Since the beginning of this year, VBIV’s stock price has dropped by -54.70% or -$1.2800, and marked a new high 1 time. However, the stock has declined by -72.18% since its 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
VBI Vaccines Inc. (VBIV) last reported insider trading activity 246 days ago on Dec 03. Beattie Nell, the Chief Business Officer of the company, purchased of 8,200 shares for $2.45 on Dec 03. It resulted in a $20,083 investment by the insider. PERCEPTIVE ADVISORS LLC sold 2,707,463 shares at an average price of $3.31 on Dec 01. The insider now owns 52,334,993 shares following the transaction.
The stock’s beta is 1.94. Besides these, the trailing price-to-sales (P/S) ratio of 590.91, the price-to-book (PB) ratio of 2.12.
In the three months ended March 30, VBI Vaccines Inc.’s quick ratio stood at 3.20, while its current ratio was 3.30, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending March 30 was 0.19, and the total debt-to-equity ratio was 0.23. Based on annual data, VBIV earned -$10.14 million in gross profit and brought in $0.63 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -39.50%. Return on equity (ROE) for the past 12 months was -48.80%.
In VBI Vaccines Inc.’s quarter-end financial report for March 30, it reported total debt of $24.79 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. VBIV’s revenue fell -130.77% during the quarter, while net income inched up to $0.13 million. While analysts expected VBI Vaccines Inc. to report -$0.08 quarterly earnings, the actual figure was -$0.08 per share. During the quarter, the company generated -$15.04 million in EBITDA. The liabilities of VBI Vaccines Inc. were 64.44 million at the end of its most recent quarter ended March 30, and its total debt was $33.39 million. The value of shareholders’ equity is $258.26 million.
This quick technical analysis looks at VBI Vaccines Inc.’s (VBIV) price momentum. With a historical volatility rate of 91.90%, the RSI 9-day stood at 72.43% on 05 August.
With respect to its five-day moving average, the current VBI Vaccines Inc. price is up by +24.60% percent or $0.2093. At present, VBIV shares trade +25.95% above its 20-day simple moving average and -16.54% percent below its 100-day simple moving average. However, the stock is currently trading approximately +25.67% above its SMA50 and -67.08% below its SMA200.
Stochastic coefficient K was 68.17% and Stochastic coefficient D was 44.97%, while ATR was 0.0870. Given the Stochastic reading of 87.10% for the 14-day period, the RSI (14) reading has been calculated as 65.10%. As of today, the MACD Oscillator reading stands at 0.0657, while the 14-day reading stands at 0.0602.
VBI Vaccines Inc. (VBIV) has been rated Buy by analysts. According to 0 brokerage firms, VBIV is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate VBI Vaccines Inc. stock as buy, with 3 recommending it as overweight.
With a median target price of $6.00, the current consensus forecast for the stock is $6.00 – $8.00. Based on these forecasts, analysts predict VBI Vaccines Inc. (VBIV) will achieve an average price target of $6.67.